Reports Q2 revenue $14.2M, consensus $12.16M. “We are exceeding many of our internal expectations,” said Intellia President and Chief Executive Officer John Leonard, M.D. “The enthusiasm from both patients and physicians for Intellia’s late-stage programs has resulted in strong enrollment numbers that allow us to plan to enhance the Phase 3 MAGNITUDE trial in ATTR-CM and accelerate completion of the Phase 3 HAELO study in HAE ahead of our original plans. We are full steam ahead in achieving our mission of getting one-time therapies to more patients.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics announces employee inducement grants
- Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN
- Regeneron and Intellia’s Promising Phase 3 Study on NTLA-2001 for ATTR-CM
- Insider Sales Shake Up Southern Co, Constellation, Intellia, US Bancorp, and Kohl’s
- Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B